Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer

  • Baykara, Meltem (Department of Medical Oncology, Sakarya University Training and Research Hospital Sakarya) ;
  • Coskun, Ugur (Department of Medical Oncology, Gazi University Medical Faculty) ;
  • Berk, Veli (Department of Medical Oncology, Erciyes University Medical Faculty) ;
  • Ozkan, Metin (Department of Medical Oncology, Erciyes University Medical Faculty) ;
  • Kaplan, Muhammet Ali (Department of Medical Oncology, Dicle University Medical Faculty) ;
  • Benekli, Mustafa (Department of Medical Oncology, Gazi University Medical Faculty) ;
  • Karaca, Halit (Department of Medical Oncology, Erciyes University Medical Faculty) ;
  • Inanc, Mevlude (Department of Medical Oncology, Erciyes University Medical Faculty) ;
  • Isikdogan, Abdurrahman (Department of Medical Oncology, Dicle University Medical Faculty) ;
  • Sevinc, Alper (Department of Medical Oncology, Gaziantep University Medical Faculty) ;
  • Elkiran, Emin Tamer (Department of Medical Oncology, Flrat University Medical Faculty) ;
  • Demirci, Umut (Department of Medical Oncology, Ankara Ataturk Training and Research Hospital) ;
  • Buyukberber, Suleyman (Department of Medical Oncology, Gazi University Medical Faculty)
  • Published : 2012.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this retrospective study was to determine response rates, progression-free survival (PFS), overall survival (OS) and toxicity of gemcitabine and paclitaxel combinations with advanced or metastatic non-small cell lung cancer patients (NSCLC) who have progressive disease after platinum-based first-line chemotherapy. Methods: We retrospectively evaluated the file records of patients treated with gemcitabine plus paclitaxel in advanced or metastatic NSCLC cases in a second-line setting. The chemotherapy schedule was as follows: gemcitabine $1500mg/m^2$ and paclitaxel 150 mg/m2 administered every two weeks. Results: Forty-eight patients (45 male, 3 female) were evaluated; stage IIIB/IV 6/42; PS0, 8.3%, PS1, 72.9%, PS2, 18.8%; median age, 56 years old (range 38-76). Six (12.5%) patients showed a partial response (PR), 13 (27.1%) stable disease (SD), and 27 (56.3%) progressive disease (PD). The median OS was 6.63 months (95% CI 4.0-9.2); the median PFS was 2.7 months (95% CI 1.8-3.6). Grade 3 and 4 hematologic toxicities, including neutropenia (n=4, 8.4%), and anemia (n=3, 6.3%) were encountered, but no grade 3 or 4 thrombocytopenia. One patient developed febrile neutropenia. There were no interruption for reasons of toxicity and no exitus related to therapy. Conclusion: The combination of two-weekly gemcitabine plus paclitaxel was an effective and well-tolerated second-line chemotherapy regimen for advanced or metastatic NSCLC patients previously treated with platinum-containing chemotherapy. Although the most common and dose limiting toxicities were neutropenia and neuropathy, this regimen was tolerated well by the patients.

Keywords

References

  1. Anderson H, Lund B, Bach F, et al (1994). Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 12, 1821-26.
  2. Androulakis N, Kouroussis C, Kakolyris S, et al (1998). Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study. Ann Oncol, 9, 1127-30. https://doi.org/10.1023/A:1008497322508
  3. Barlesi F, Jacot W, Astoul P, et al (2006). Second line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer, 51, 159-72 https://doi.org/10.1016/j.lungcan.2005.08.017
  4. Bhatia S, Hanna N, Ansari R, et al (2009). A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer, 38, 73-77.
  5. Bonomi P, Paz-Ares L, Langer C, et al (2005). Xyotax versus docetaxel for the second-line treatment of non-small-cell lung cancer: the STELLAR 2 phase III study. Lung Cancer, 49, S35.
  6. Bunn PA Jr, Kelly K (1998). New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res, 4, 1087-90.
  7. Cappuzzo F, Ciuleanu T, Stelmakh L, et al (2010). Erlotinib as maintenance treatment in A-NSCLC: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol, 11, 521-9. https://doi.org/10.1016/S1470-2045(10)70112-1
  8. Caponi S, Vasile E, Ginocchi L, et al (2010). Second-line treatment for non-small-cell lung cancer: one size does not fit all. Clin Lung Cancer, 11, 320-7. https://doi.org/10.3816/CLC.2010.n.040
  9. Comellaa P, Chiurib EC, Cataldisc G, et al (2010). Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer A randomized phase II SICOG trial. Lung Cancer, 68, 94-98 https://doi.org/10.1016/j.lungcan.2009.05.008
  10. Coskun U, Kaya AO, Buyukberber S, et al (2008). Single agent gemcitabine in the second-line treatment of advanced nonsmall cell lung cancer after treatment with taxane + platinum regimens. Med Oncol, 25, 133-6. https://doi.org/10.1007/s12032-007-9005-3
  11. Crino L, Scagliotti G, Marangolo M, et al (1997). Cisplatingemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol, 15, 297-03.
  12. Crino L, Mosconi AM, Scagliotti G, et al (1999). Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol, 17, 2081-85.
  13. Cullen M (2006). Second-line treatment options in advanced nonsmall cell lung cancer: current status. Semin Oncol, 33, S3-S8. https://doi.org/10.1053/S0093-7754(06)00402-7
  14. Cullen MH, Zatloukal P, Sorenson S, et al (2008). A randomized phase III trial comparing standard and high dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer. Ann Oncol, 19, 939-45. https://doi.org/10.1093/annonc/mdm592
  15. Delbaldo C, Michiels S, Syz N, et al (2004). Benefit of adding a drug to a single agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysis. JAMA, 292, 470-84. https://doi.org/10.1001/jama.292.4.470
  16. De Marinis F, Grossi F (2008). Clinical evidences for second-and third-line treatment options in advanced non-small cell lung cancer. Oncologist, 13, 14-20.
  17. De Marinis F, Ricciardi S (2011). Second-line treatment options in advanced non-small cell lung cancer. Eur J Cancer, 47, S258-71.
  18. Di Maio M, Lama N, Morabito A, et al (2010). Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Eur J Cancer, 46, 735-43. https://doi.org/10.1016/j.ejca.2009.12.013
  19. Di Maio M, Chiodini P, Georgoulias V, et al (2009). Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-smallcell lung cancer. J Clin Oncol, 27, 1836-43. https://doi.org/10.1200/JCO.2008.17.5844
  20. Douillard JY, Shepherd FA, Hirsh V, et al (2010). Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol, 28, 744-52. https://doi.org/10.1200/JCO.2009.24.3030
  21. Fossella FV, DeVore R, Kerr RN, et al (2000). Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum- containing chemotherapy regimens. J Clin Oncol, 18, 2354-62.
  22. Gatzemeier U, Heckmayer M, Neuhauss R, et al (1995). Chemotherapy of advanced noperable non-small cell lung cancer with paclitaxel: a phase II trial. Semin Oncol, 22, 24-8.
  23. Gebbia V, Gridelli C, Verusio C, et al (2009). Weekly docetaxel vs. docetaxel-based combination chemotherapy as secondline treatment of advanced nonsmall-cell lung cancer patients: The DISTAL-2 randomized trial. Lung Cancer, 63, 251-8. https://doi.org/10.1016/j.lungcan.2008.05.027
  24. Georgoulias V, Kouroussis C, Agelidou A, et al (2004). Irinotecan plus gemcitabine vs irinotecan for the secondline treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: A multicentre, randomised, phase II study. Br J Cancer, 91, 482-8. https://doi.org/10.1038/sj.bjc.6602010
  25. Georgoulias V, Agelidou A, Syrigos K, et al (2005). Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomised phase II study. Br J Cancer, 93, 763-9. https://doi.org/10.1038/sj.bjc.6602748
  26. Gridelli C, Perrone F, Gallo C, et al (1999). Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res, 9, 4535-8.
  27. Gridelli C, Ardizzoni A, Ciardiello F, et al (2008). Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol, 3, 430-40 https://doi.org/10.1097/JTO.0b013e318168c815
  28. Grilli R, Oxman AD, Julian JA (1993). Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. J Clin Oncol, 11, 1866-72.
  29. Hainsworth JD, Thompson DS, Greco FA (1995). Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol, 13, 1609-14.
  30. Hanna N, Shepherd FA, Fossella FV, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
  31. Huang CH, Millenson MM, Sherman EJ, et al (2008). Promising Survival in Patients with Recurrent Non-small Cell Lung Cancer Treated with Docetaxel and Gemcitabine in Combination as Second-Line Therapy. J Thorac Oncol, 3, 1032-8 https://doi.org/10.1097/JTO.0b013e31818307c2
  32. Isla D, Rosell R, Sánchez JJ, et al (2001). Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol, 19, 1071-7.
  33. Kim ES, Hirsch V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST): A randomised phase III trial. Lancet, 372, 1809-18. https://doi.org/10.1016/S0140-6736(08)61758-4
  34. Klastersky J, Awada A (2012). Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC). Crit Rev Oncol Hematol, 81, 49-57.
  35. Kosmas C, Tsavaris N, Syrigos K, et al (2007). A phase I-II study of bi-weekly gemcitabine and irinotecan as secondline chemotherapy in non-small cell lung cancer after prior taxane+platinum-based regimens. Cancer Chemother Pharmacol, 59, 51-9.
  36. Kosmidis PA, Kalofonos HP, Christodoulou C, et al (2008). Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol, 19, 115-22.
  37. Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T (2007). Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced nonsmall cell lung cancer after treatment with platinum-based chemotherapy. Cancer Chemother Pharmacol, 60, 189-95 https://doi.org/10.1007/s00280-006-0360-0
  38. Paz-Ares L, Ross H, O'Brien M, et al (2008). Phase III trial comparing paclitaxel poliglumex vs. docetaxel in the secondline treatment of non-small-cell lung cancer (NSCLC). Br J Cancer, 98, 1608-13. https://doi.org/10.1038/sj.bjc.6604372
  39. Pectasides D, Pectasides M, Farmakis D, et al (2005). Comparison of docetaxel and docetaxelirinotecan combination as secondline chemotherapy in advanced non-small-cell lung cancer: A randomized phase II trial. Ann Oncol, 16, 294-9. https://doi.org/10.1093/annonc/mdi053
  40. Pino MS, Gamucci T, Mansueto G, et al (2008). A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weeklypaclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer, 60, 381-6. https://doi.org/10.1016/j.lungcan.2007.10.027
  41. Reck M, van Zandwijk N, Gridelli C, et al (2010). Erlotinib in advanced non-small cell lung cancer - efficacy and safety findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. J Thorac Oncol, 5, 1616-22. https://doi.org/10.1097/JTO.0b013e3181f1c7b0
  42. Scagliotti G, Hanna N, Fossella F, et al (2009). The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist, 14, 253-63. https://doi.org/10.1634/theoncologist.2008-0232
  43. Shepherd FA (1993). Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol, 5, 310-22. https://doi.org/10.1097/00001622-199303000-00010
  44. Shepherd FA, Abratt R, Crino L, et al (2000). The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer, 30, 117-25. https://doi.org/10.1016/S0169-5002(00)00135-5
  45. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 353, 123-32. https://doi.org/10.1056/NEJMoa050753
  46. Shepherd FA, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
  47. Smit EF, van Meerbeeck JPAM, Lianes P, et al (2003). Three-arm randomized study of two cisplatin-based regimen and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group- EORTC 08975. J Clin Oncol, 3, 3909-17.
  48. Smit EF, Groen HJ, Smit HJ, et al (2008). A randomized phase II study of pemetrexed (P) versus pemetrexed-carboplatin (PC) as second line treatment for patients (pts) with advanced non-small-cell lung cancer (NSCLC)-NVALT 7. J Clin Oncol, 26, 436.
  49. Socinski MA, Steagall A, Gillenwater H (1999). Secondline chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Invest, 17, 181-8. https://doi.org/10.3109/07357909909021419
  50. Stinchombe TE, Socinski MA (2008). Considerations for secondline therapy of non-small cell lung cancer. Oncologist, 13, 28-36 https://doi.org/10.1634/theoncologist.13-S1-28
  51. Takeda K, Negoro S, Tamura T, et al (2009). Phase III trail of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: Results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol, 20, 835-41. https://doi.org/10.1093/annonc/mdn705
  52. Thatcher N, Chang A, Parikh P, et al (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet, 366, 1527-37. https://doi.org/10.1016/S0140-6736(05)67625-8
  53. Treat J, Belani CP, Edelman MJ, et al (2005). A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced stage IIIB IV non-small cell lung cancer (NSCLC). Update on the Alpha oncology trial (A1-99002L). Proc Soc Am Clin Oncol, 23, 627.
  54. Tucker S (2010). The role of pemetrexed in second-line chemotherapy for advanced non-small cell lung cancer. Curr Drug Targets,11, 58-60. https://doi.org/10.2174/138945010790031036
  55. Vamvakas L, Angelaki S, Kentepozidis NK, et al (2010). Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial. J Clin Oncol, 28, 15s
  56. Wachters FM, Groen HJ, Biesma B, et al (2005). A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV nonsmall- cell lung cancer who failed first-line treatment. Br J Cancer, 92, 15-20. https://doi.org/10.1038/sj.bjc.6602268
  57. Walling J (1994). Chemotherapy for advanced non-small-cell lung cancer. Respir Med, 88, 649-57. https://doi.org/10.1016/S0954-6111(05)80061-7